Cancer Drugs Poised to Improve as New Developments Help Previous Therapies Target Better - Seite 4

Oncolytics has 398 patents issued worldwide, including 48 US and 21 Canadian, with over 21 more pending applications worldwide. The reovirus issued patent claims cover compositions of matter comprising reovirus (through 2028 and extendable to 2033), and all pharmaceutical uses of it.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is implementing a multifaceted approach to fighting cancer. Among its key assets, the company has its fully human antibodies G-MAB library, clinical stage immuno-cellular therapies CAR-T, intracellular targeting antibodies iTAbs, antibody-drug conjugates ADC, and clinical stage oncolytic virus Seprehvir.

AstraZeneca PLC (NYSE:AZN) doubled down on oncolytic viruses when it invested $10 million into a deal with France's Transgene. This was a follow-up on a previous 2015 deal with Omnis Pharmaceuticals. With Transgene, AstraZeneca is set to develop five armed OVs.

Moving forward, many eyes will be on the partnership between BioNTech SE (NASDAQ:BNTX) and Sanofi (NASDAQ:SNY). Sanofi invested over $90 million into BioNTech to start clinical development of the first cancer immunotherapy to come from their original 2015 pact. Sanofi is set to pay up to $300 million in milestones per asset.

Read more about Oncolytics Biotech here: https://usanewsgroup.com/2019/10/06/what-if-you-could-teach-your-body-to-fight-cancer/

Article Source:
USA News Group
http://usanewsgroup.com
[e-mail]

Legal Disclaimer/Disclosure:

This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of USA News Group only and are subject to change without notice. USA News Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.